Review article: Benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2009, Pages 161-171

  Mitry, E ^a,b   Rougier, P ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; GERIATRIC PATIENT; HUMAN; LEUKOPENIA; LIVER TOXICITY; METASTASIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM METASTASIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 57649198674     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03867.x     Document Type: Review

References (62)

1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002 94 : 2766 92.
2. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD : National Cancer Institute, 2007. Available at: http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site.
3. American Cancer Society. Cancer Facts & Figures. 2006. Available at: http://www.cancer.org/docroot/STT/stt_O_2006.asp?sitearea=STT&level=1
4. Mitry E, Douillard JY, Van CE, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004 15 : 1013 7.
5. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006 36 : 216 20.
6. Faivre J, Lemmens VE, Quipourt V, Bouvier AM. Management and survival of colorectal cancer in the elderly in population-based studies. Eur J Cancer 2007 43 : 2279 84.
7. Pasetto LM, Stefano T, Rossi E, Paris MK, Monfardini S. Treatment of stage IV colorectal carcinoma in elderly patients. Crit Rev Oncol Hematol 2005 54 : 145 55.
8. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006 24 : 4085 91.
9. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol 2007 25 : 1832 43.
10. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer 1994 74 (Suppl. 7 2208 14.
11. Townsley C, Pond GR, Peloza B, et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005 23 : 3802 10.
12. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003 21 : 1383 9.
13. Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 2005 23 : 2201 7.
14. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000 343 : 905 14.
15. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 355 : 1041 7.
16. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 18 : 2938 47.
17. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004 22 : 1209 14.
18. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005 23 : 9441 2.
19. Bouché O, Castaing M, Etienne PL, et al. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19-21 January, 2007, Orlando, FL. Abstract 4069.
20. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007 370 : 143 52.
21. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007 370 : 135 42.
22. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42.
23. Grothey A, Sugrue M, Hedrick E, BRiTe Study Investigators. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J Clin Oncol 2007 25 (18S 1725, Abstract 4036.
24. Kozloff M, Hainsworth J, Badarinath S. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006 24 (18S 1555, Abstract 3537.
25. Kretzschmar A, Cunningham D, Berry S, First BEAT Investigators. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the first BEATrial. American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January, 2006, San Francisco, CA. Abstract 248.
26. Van Cutsem E, Michael M, Berry S, First BEAT Investigators. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI, and capecitabine for mCRC: first BEATrial. American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January, 2006, San Francisco, CA. Abstract 250.
27. Wedding U, Honecker F, Bokemeyer C, Pientka L, Hoffken K. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007 14 : 44 56.
28. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007 25 : 1824 31.
29. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003 1 (Suppl. 2 18 24.
30. Balducci L. Myelosuppression and its consequences in elderly patients with cancer. Oncology (Williston Park) 2003 17 (Suppl. 11 27 32.
31. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000 35 : 181 200.
32. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004 59 : 255 63.
33. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998 16 : 1582 7.
34. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987 40 : 373 83.
35. Audisio RA, Ramesh H, Longo WE, Zbar AP, Pope D. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist 2005 10 : 262 8.
36. Balducci L. New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol 2003 1 (Suppl. 2 30 7.
37. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005 55 : 241 52.
38. Wedding U, Kodding D, Pientka L, Steinmetz HT, Schmitz S. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007 64 : 1 9.
39. Reddy N, Yu J, Fakih MG. Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer 2007 6 : 362 6.
40. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004 15 : 1330 8.
41. Hochster HS, Luo W, Popa EC, et al. Phase II study of uracil-tegafur with leucovorin in elderly (≥75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 2007 25 : 5397 402.
42. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001 19 : 2282 92.
43. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004 90 : 1190 7.
44. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005 23 : 3104 11.
45. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006 24 : 394 400.
46. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007 110 : 2666 71.
47. Berretta M, Bearz A, Frustaci S, et al. FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients. Ann Oncol 2006 17 : 1606 7.
48. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005 104 : 282 9.
49. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005 23 : 3545 51.
50. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008 26 : 1443 51.
51. Mitry E, Phelip JM, Bonnetain F, et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD 2001-02 trial. Results of a planned interim analysis. American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January, 2008, Orlando, FL. Abstract 3524.
52. Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 2006 92 : 290 4.
53. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007 25 : 4779 86.
54. Barrueco J, Marshall J, Mitchell E, et al. Safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those <65: the BICC-C study. J Clin Oncol 2007 25 (18S 1825, Abstract 4076.
55. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008 26 : 689 90.
56. Kozloff M, Sugrue M, Berlin J, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE Prospective Cohort Study. American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January, 2008, Orlando, FL.
57. Puthillath AA, Mashtare T, Wilding G, Ross M, Fakih MG. A phase II study of first-line biweekly regimen of capecitabine (CAP) and bevacizumab (BV) in elderly patients with metastatic colorectal cancer. 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 25-27 January, 2008, Orlando, FL. Abstract 511.
58. Figueras J, Ramos E, Lopez-Ben S, et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clin Transl Oncol 2007 9 : 392 400.
59. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007 14 : 7 12.
60. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007 12 : 1416 24.
61. Balducci L. Management of chemotherapy-induced neutropenia in the older cancer patient. Oncology (Williston Park) 2006 20 (Suppl. 9 26 31.
62. Extermann M, Albrand G, Chen H, et al. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 2003 21 : 3214 9.